GlassScriptPhysician profile
Margaret Bates Mccormack
NPI 1376809053
$9,001.11
in general payments reported to CMS, 2019-2025
53 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,369 · 2020: $993 · 2021: $1,453 · 2022: $1,616 · 2023: $1,576 · 2024: $935 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,571.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,004.03 | 2019-2025 | Evenity, Repatha, Repatha |
| Novo Nordisk INC | $968.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $891.81 | 2021-2025 | |
| Esperion Therapeutics, INC. | $586.25 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $556.29 | 2019-2025 | |
| Lilly USA, LLC | $511.24 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $503.07 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $464.67 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $422.42 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $422.07 | 2019-2025 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $300.80 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $276.65 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $244.82 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $196.73 | 2022 | |
| Sanofi-Aventis U.S. LLC | $136.87 | 2019-2020 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Mccormack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.